The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...

PR Newswire CAESAREA, Israel IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel /PRNewswire/ -- IceCure Medi ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

Proving your product to be safe and effective while also getting buy-in from the healthcare ecosystem are only some of the ...

Background: Cryoablation (CRYO) is an alternative to radiofrequency (RF) ablation in the treatment of atrioventricular nodal reentrant tachycardia (AVNRT). This study aims to evaluate the ...

Led by researchers at NYU Grossman School of Medicine, the study tracked patient outcomes after primary partial gland cryoablation (PPGCA), a procedure where only the cancerous part of the ...

About Adagio Medical Holdings, Inc. Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is an early commercial stage medical device company located in Laguna Hills, California focused on developing ...

Cryoablation devicemaker Adagio Medical has ... The ultralow-temperature device uses liquid nitrogen to reach -196 degrees Celsius and rapidly freeze the heart tissue that drives potentially ...

is an early commercial stage medical device company located in Laguna Hills, California focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous ...

The trial, being conducted under an investigational device exemption (IDE) from the Food and Drug Administration (FDA), is evaluating the safety and effectiveness of the Adagio VT cryoablation system ...